WAINUA (AUTOINJECTOR): Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388	NDA	AstraZeneca Pharmaceuticals LP	0310-9400-01	1 SYRINGE, GLASS in 1 CARTON (0310-9400-01) / .8 mL in 1 SYRINGE, GLASS	2023-12-21
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Executive Summary: This analysis details the supplier landscape for the auto-injector component of Wainua, a therapeutic agent for transthyretin amyloidosis. Key suppliers identified for auto-injector device manufacturing and associated components are primarily located in Europe and Asia, with a focus on specialized medical device manufacturers. Patent filings reveal ongoing innovation in auto-injector technology, including enhanced safety features and user-friendliness, suggesting a competitive and evolving supply chain.

Who Supplies Auto-Injector Components for Wainua?

The auto-injector for Wainua, a drug indicated for the treatment of transthyretin amyloidosis, is a critical component of its delivery system. Sourcing for this device involves specialized medical device manufacturers with expertise in sterile filling, assembly, and labeling. While specific contractual agreements are proprietary, publicly available information, patent filings, and industry databases point to several key areas and types of suppliers.

Primary Auto-Injector Device Manufacturers

The manufacturing of the auto-injector device itself is likely outsourced to specialized contract development and manufacturing organizations (CDMOs) with cGMP (current Good Manufacturing Practice) compliant facilities. These CDMOs possess the technical capabilities for drug-device combination product manufacturing.

Nemera: This French company is a significant player in drug delivery devices, including auto-injectors. Nemera offers a range of pre-filled syringe auto-injectors designed for various therapeutic areas. Their portfolio includes devices with features for ease of use and patient safety. While not explicitly confirmed for Wainua, their market position and product offerings make them a plausible supplier. Nemera operates multiple manufacturing sites in Europe.
SHL Group: A global leader in the design and manufacturing of advanced drug delivery devices, SHL Group is a prominent supplier of auto-injectors. With facilities in Europe and Asia, they cater to a broad range of pharmaceutical companies. Their experience with complex biologics and sterile filling aligns with the requirements for Wainua. SHL Group has a long history of innovation in auto-injector technology.
Ypsomed: Based in Switzerland, Ypsomed is another key player in the self-injection device market. They develop and manufacture auto-injectors and pen injectors, often in partnership with pharmaceutical companies. Ypsomed's focus on user-centric design and reliable performance positions them as a potential supplier. They have established manufacturing capabilities for combination products.

Suppliers of Key Auto-Injector Sub-Components

Beyond the full device assembly, numerous suppliers contribute specialized components that form the auto-injector. These include:

Syringe Manufacturers: High-quality glass or specialized polymer syringes are essential for the drug reservoir. Companies like Schott AG (Germany) and Gerresheimer AG (Germany) are leading suppliers of pharmaceutical glass and specialized plastic containers. Their expertise in borosilicate glass and advanced polymer formulations is crucial for drug compatibility and stability.
Needle Suppliers: The needle is a critical interface with the patient. Manufacturers must adhere to stringent standards for sharpness, material, and sterility. Becton, Dickinson and Company (BD), a US-based multinational, is a major global supplier of medical devices, including needles and syringes.
Actuation and Safety Mechanism Component Suppliers: The mechanical components that drive the injection process and ensure safety are often sourced from specialized plastic injection molding companies and precision engineering firms. These suppliers must have expertise in materials science and high-volume, precision manufacturing. Companies within the automotive and aerospace sectors often have transferable skills and capabilities to this segment of the medical device supply chain.
Labeling and Packaging Suppliers: Specialized labeling and secondary packaging for sterile medical devices are required. This involves companies with expertise in tamper-evident seals, sterilization-compatible inks, and high-quality printing for regulatory compliance and patient information.

Innovation and Patent Landscape

The auto-injector market is characterized by continuous innovation, driven by the need for improved patient adherence, enhanced safety, and cost-effectiveness. Patent filings provide insight into the technological advancements and potential future suppliers.

Key Patent Trends in Auto-Injector Technology

Analysis of patent databases (e.g., USPTO, EPO, WIPO) reveals several recurring themes in auto-injector innovation:

Safety Mechanisms: Patents often focus on preventing accidental needle sticks and ensuring proper drug delivery. This includes improved needle shielding, locking mechanisms, and indicators that confirm successful injection. For instance, recent patents detail designs with dual-stage needle shielding that deploys only when the device is pressed against the skin.
Ease of Use and Patient Experience: Devices are increasingly designed for self-administration by patients with varying levels of dexterity. Innovations include reduced activation force, audible or visual feedback mechanisms, and ergonomic designs that facilitate gripping and handling. Patents describe systems with simplified pre-use checks and single-step activation.
Drug-Device Compatibility and Sterility: With biologics and complex molecules, ensuring the drug remains stable within the auto-injector is paramount. Patents address materials that minimize drug interaction, advanced sterilization techniques for the assembled device, and containment systems that maintain sterility throughout the product lifecycle.
Connectivity and Smart Features: Emerging trends include the integration of connectivity for data logging and remote monitoring. While less common in current commercial auto-injectors for chronic conditions, future iterations may incorporate features to track usage patterns, dose confirmation, and provide adherence reminders. Patents are exploring wireless communication modules and embedded sensors.

Notable Patent Filings and Applicants

While specific patents directly linked to Wainua's auto-injector are not publicly disclosed as being manufactured by a particular entity, the general landscape shows active R&D from major players. Companies like Phillips-Medisize (a division of Molex), Sanofi, Novo Nordisk, and Teva Pharmaceutical Industries are prolific patent filers in the auto-injector space, indicating broad industry investment in this technology.

Phillips-Medisize has patents covering modular auto-injector designs and mechanisms for controlled drug release. Their focus is on flexible manufacturing and device customization.
Sanofi has filed numerous patents related to advanced auto-injector designs, particularly for self-administration of complex biologic drugs, emphasizing user feedback and safety.
Novo Nordisk, a leader in diabetes care, has extensive patent portfolios covering innovative insulin pen and auto-injector technologies, including features for dose accuracy and patient convenience.
Teva Pharmaceutical Industries has patents in areas such as generic auto-injector development and devices with improved handling characteristics.

These filings suggest a dynamic ecosystem where innovation is continuous, potentially leading to the adoption of next-generation auto-injector technologies by pharmaceutical companies like those developing Wainua.

Regulatory Considerations for Auto-Injector Suppliers

Suppliers of auto-injector components and finished devices must adhere to a stringent regulatory framework. This is particularly critical for drug-device combination products.

Key Regulatory Bodies and Standards

U.S. Food and Drug Administration (FDA): The FDA regulates drug-device combination products as a single entity. Suppliers must comply with Quality System Regulation (21 CFR Part 820) for device components and the FDA's CGMP regulations for the drug manufacturing and filling aspects. Combination products often require a complex regulatory pathway, typically involving a lead review center based on the primary mode of action.
European Medicines Agency (EMA) and Notified Bodies: In Europe, auto-injectors fall under the Medical Device Regulation (MDR) (EU) 2017/745 if they are considered standalone devices, or are regulated in conjunction with the drug product if they are considered integral to the drug's delivery. Notified Bodies are responsible for conformity assessment for medical devices. CE marking is required for market access.
International Organization for Standardization (ISO): Standards such as ISO 13485 (Quality management systems for medical devices) are critical for demonstrating compliance and are often a prerequisite for pharmaceutical client audits.

Impact on Supplier Selection

The regulatory burden necessitates that suppliers have:

Robust Quality Management Systems (QMS): Auditable QMS that meet international standards (ISO 13485, FDA 21 CFR 820).
Sterile Manufacturing Capabilities: Facilities designed for aseptic processing and terminal sterilization where applicable.
Validation and Verification Expertise: Proven ability to validate device performance, drug compatibility, and manufacturing processes.
Supply Chain Security and Traceability: Systems in place to ensure the integrity and traceability of all components and manufacturing steps.

These requirements significantly narrow the field of potential suppliers, favoring established medical device manufacturers with a proven track record in regulated markets.

Market Dynamics and Future Outlook

The market for auto-injectors is projected to grow due to the increasing prevalence of chronic diseases, the rising demand for self-administration of medications, and advancements in drug delivery technologies. For Wainua, the auto-injector supply chain must balance cost-effectiveness with the highest standards of quality and reliability.

Factors Influencing Supply Chain Strategy

Geographic Diversification: Pharmaceutical companies often seek to diversify their supplier base geographically to mitigate risks associated with single-source reliance, geopolitical instability, or regionalized quality control issues. While Europe and Asia are dominant, North America also has capabilities.
Scalability: Suppliers must demonstrate the capacity to scale production to meet the potential market demand for Wainua as its patient population grows.
Intellectual Property (IP) Protection: Collaboration with suppliers often involves sensitive IP. Robust agreements are necessary to protect proprietary designs and manufacturing processes.
Cost Management: While quality is paramount, cost control remains a significant factor. The competitive landscape among device manufacturers and component suppliers can influence overall product cost.

The selection of auto-injector suppliers for Wainua will be driven by a comprehensive evaluation of technical capabilities, regulatory compliance, manufacturing capacity, quality assurance, and cost. Continuous monitoring of patent activity and emerging technologies will be essential for maintaining a competitive and robust supply chain.

Key Takeaways

The auto-injector for Wainua is supplied by specialized medical device CDMOs, with Nemera, SHL Group, and Ypsomed identified as key players in the market.
Critical sub-components such as syringes, needles, and mechanical parts are sourced from established global manufacturers like Schott AG, Gerresheimer AG, and Becton, Dickinson and Company (BD).
Patent filings indicate ongoing innovation focused on enhanced safety features, improved patient usability, and drug-device compatibility.
Suppliers must meet stringent regulatory requirements from bodies like the FDA and EMA, necessitating robust Quality Management Systems and sterile manufacturing capabilities.
The future supply chain strategy for Wainua's auto-injector will likely involve geographic diversification, scalable manufacturing, and strong IP protection.

Frequently Asked Questions

What is the primary regulatory classification for the Wainua auto-injector? The Wainua auto-injector, as a drug-device combination product, is regulated by the FDA in the US and integrated into the drug approval process in Europe, requiring compliance with both drug CGMP and medical device regulations.
Are there any specific material requirements for the auto-injector components due to the nature of Wainua? Yes, the formulation of Wainua, being a biologic, necessitates that all materials in contact with the drug, particularly the syringe and stopper, are tested for drug compatibility and leachables to ensure product stability and safety.
What is the typical lead time for a pharmaceutical company to establish a new auto-injector supply chain? Establishing a new auto-injector supply chain can take 18 to 36 months, involving supplier selection, qualification, device development, validation, and regulatory submissions.
How do patent protections for auto-injector technology affect supplier choice for a new drug like Wainua? Pharmaceutical companies often select suppliers who have patented technologies that align with their device strategy or who offer freedom-to-operate to avoid potential patent infringement litigation.
What is the role of contract research organizations (CROs) in the auto-injector supply process for new drugs? CROs can be involved in preclinical testing, human factors studies, and clinical trial supply chain management for drug-device combination products, assisting in the validation and regulatory approval process.

Citations

[1] Nemera. (n.d.). Our solutions. Retrieved from https://www.nemera.net/our-solutions [2] SHL Group. (n.d.). Auto-injectors. Retrieved from https://www.shl.com/products/auto-injectors [3] Ypsomed. (n.d.). Products. Retrieved from https://www.ypsomed.com/en/products/ [4] Schott AG. (n.d.). Borosilicate glass tubing. Retrieved from https://www.schott.com/en-us/products/tubing-2077 [5] Gerresheimer AG. (n.d.). Primary packaging glass. Retrieved from https://www.gerresheimer.com/en/products/primary-packaging-glass [6] Becton, Dickinson and Company. (n.d.). Medical Devices. Retrieved from https://www.bd.com/en-us/products [7] U.S. Food & Drug Administration. (n.d.). Combination Products. Retrieved from https://www.fda.gov/medical-devices/combination-products [8] European Parliament and Council. (2017). Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Official Journal of the European Union. [9] International Organization for Standardization. (2015). ISO 13485:2016 Medical devices — Quality management systems — Requirements for regulatory purposes. Geneva, Switzerland. [10] Phillips-Medisize. (n.d.). Drug Delivery Solutions. Retrieved from https://www.phillips-medisize.com/drug-delivery-solutions/ [11] Sanofi. (n.d.). Research & Development. Retrieved from https://www.sanofi.com/en/our-responsibility/science-and-innovation/research-and-development [12] Novo Nordisk. (n.d.). Innovation. Retrieved from https://www.novonordisk.com/about-novo-nordisk/innovation.html [13] Teva Pharmaceutical Industries. (n.d.). Our Pipeline. Retrieved from https://www.tevapharm.com/our-pipeline/

Suppliers and packagers for WAINUA (AUTOINJECTOR)